Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
John P H WildingRachel L BatterhamMelanie Jane DaviesLuc F Van GaalKristian KandlerKaterina KonakliIldiko LingvayBarbara M McGowanTugce Kalayci OralJulio RosenstockThomas A WaddenSean WhartonKoutaro YokoteRobert F Kushnernull nullPublished in: Diabetes, obesity & metabolism (2022)
One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.
Keyphrases
- weight loss
- gastric bypass
- bariatric surgery
- roux en y gastric bypass
- weight gain
- randomized controlled trial
- public health
- healthcare
- clinical trial
- study protocol
- glycemic control
- obese patients
- physical activity
- metabolic syndrome
- body mass index
- phase ii
- skeletal muscle
- risk assessment
- adipose tissue
- smoking cessation